Similarly, blocking TRAIL by injecting its soluble receptor DR5 into cyclophosphamide (CY)-treated NOD mice, to accelerate diabetes onset, resulted in disease characteristics similar to those seen in TRAIL-deficient mice treated with STZ. Here, TNFSF10 is linked to diabetes mellitus.